Replies to post #119786 on Biotech Values

[DFRAI]

Microcapfun

They sure dont look like dragging things out to me. They seem to expand testing in various other cancers and especially for RAS activated cancers and some of the hardest to treat type...but you did not bother to read about it...and that is ok, i understand that it does not work based on your overall experience/knowledge.

that is what makes a market for me.

http://www.oncolyticsbiotech.com/clinical.html - clinical trials

http://www.clinicaltrials.gov/ct2/show/NCT01166542?term=reolysin&rank=2 - this is the phase III

Principal Investigator: James A Bonner, MD University of Alabama at Birmingham, Birmingham, AB, US
Principal Investigator: Kevin Harrington, MBBS MRCP FRCR The Royal Marsden Hospital, London, UK
Principal Investigator: Jan Vermorken, MD, PhD University Hospital, Antwerp, Belgium

I would say the investigators have pretty good reputation in their fields.

It doesn't look like ONCY is timid - as they selected very tough patients - •have recurrent or metastatic (R/M) histologically confirmed squamous cell carcinoma (SCC) of the head and neck (oropharynx, oral cavity, larynx, hypopharynx) or squamous cell nasopharynx cancer (NPC) with distal metastasis(es) and no secondary cancers (Patients with NPC without distal metastasis(es) or with undifferentiated NPC are not eligible).

Was it Amgen that paid 1 billion for one of their private competitors - 2,3 months ago...i guess it does not work for anybody...what is 1 billion down the drain. I guess they did not look to your for investment advice, altough they did not call me either. Later.